Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as high-dose Group ACYW135X Meningococcal Conjugate Vaccine
Group ACYW135X Meningococcal Conjugate Vaccine · 1 trial · 1 indication
The incidence rates of adverse reactions 30 days after vaccination
| Arm | Type | Description |
|---|---|---|
| high-dose experimental group | EXPERIMENTAL | 2\~59 years old |
| medium-dose experimental group | EXPERIMENTAL | 2\~59 years old |
| low-dose experimental group | EXPERIMENTAL | 2\~6 years old |
| placebo group | PLACEBO_COMPARATOR | 2\~6 years old |
| active control group | ACTIVE_COMPARATOR | 2\~3 years old |
| Name | Type | Description |
|---|---|---|
| high-dose Group ACYW135X Meningococcal Conjugate Vaccine | BIOLOGICAL | high-dose Group ACYW135X Meningococcal Conjugate Vaccine |
| medium-dose Group ACYW135X Meningococcal Conjugate Vaccine | BIOLOGICAL | medium-dose Group ACYW135X Meningococcal Conjugate Vaccine |
| low-dose Group ACYW135X Meningococcal Conjugate Vaccine | BIOLOGICAL | low-dose Group ACYW135X Meningococcal Conjugate Vaccine |
| Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) | BIOLOGICAL | Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) |
| Placebo | BIOLOGICAL | placebo |
Inclusion Criteria: * Healthy participants aged 2 to 59 years; * The participant and/or their legal guardian can understand and voluntarily sign the informed consent form (for participants aged 8 to 17 years, the form must be signed jointly by the participant and their legal guardian); * Be willing...